Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - RESPONSE BIOMEDICAL CORP | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
August 16, 2012
RESPONSE BIOMEDICAL CORP.
(Exact name of registrant as specified in its charter)
|
Vancouver, British Columbia,
Canada
|
000-50571
|
98 -1042523
|
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
1781 - 75th Avenue W.
Vancouver, British Columbia, Canada V6P 6P2
(Address of principal executive offices, including zip code)
(604) 456-6010
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events
On August 16, 2012, Response Biomedical Corp., or the Company, issued a press release regarding the status of the implementation of the previously announced consolidation of the issued and outstanding common shares of the Company, which was approved by the Company’s shareholders on June 19, 2012. The press release is attached hereto as Exhibit 99.1.
The information in this Item 8.01 and Exhibit 99.1 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) and shall not be deemed to be incorporated by reference into any filing under the Securities Act, or the Exchange Act, except to the extent that we specifically incorporate it by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release, dated August 16, 2012
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
RESPONSE BIOMEDICAL CORP.
|
|||
|
By:
|
/s/W.J. Bill Adams
|
||
|
W.J. Bill Adams
Chief Financial Officer
|
|||
Date: August 20, 2012
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release, dated August 16, 2012
|